Do Patients with High Risk or Relapsed Core Binding Factor Acute Myeloid Leukemia Benefit from Salvage Allogeneic Stem Cell Transplantation?
β Scribed by Hobbs, Gabriela; Kishtagari, Ashwin; Hilden, Patrick; Barker, Juliet N.; Jakubowski, Ann A.; Papadopoulos, Esperanza; Devlin, Sean; Boulad, Farid; Kernan, Nancy; Kobos, Rachel; Steinherz, Peter G.; O'Reilly, Richard; Giralt, Sergio A.; Tallman, Martin; Stein, Eytan; Perales, Miguel-Angel
- Book ID
- 122256450
- Publisher
- Elsevier Science
- Year
- 2014
- Tongue
- English
- Weight
- 307 KB
- Volume
- 20
- Category
- Article
- ISSN
- 1083-8791
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract In this uniβcentre retrospective study, we studied 120 adults with acute myeloid leukaemia (AML) (__n__β=β88) and myelodysplastic syndrome (MDS) (__n__β=β32) who received first allogeneic HSCT to determine prognostic factors which are correlated with the outcome after myeloablative (MA)